Repligen Reports Q3 2026 Revenue Growth Driven by Chromatography and Proteins
Repligen Corporation (RGEN) reported third-quarter revenue of $209.3 million, marking an 11% reported increase and a 12.5% organic growth rate. The performance was primarily driven by significant expansions in the chromatography segment, which grew over 50%, and the proteins segment, which saw growth exceeding 40%. Despite these gains, filtration revenue declined by 11% due to divestments and timing issues regarding system deliveries. The company updated its full-year 2026 revenue guidance to a range of $844 million to $852 million, incorporating the impact of the BioLife acquisition. While capital equipment orders reached a five-year high, management noted that revenue recognition for these orders has been delayed. Looking ahead, Repligen expects the BioLife integration to be accretive to earnings per share starting in 2027.
Tickers: $RGEN
Topics: acquisition chromatography eps guidance proteins revenue growth